Dodge & Cox Reduces $47M in Haleon plc ($HLN)
Key Points
- Dodge & Cox changed its Haleon plc ($HLN) stake by 3.4% last quarter, cutting to 146,539,663 shares worth $1.32 billion.
- Wall Street's consensus rating on $HLN is Buy and an average price target of $11.74.
- $HLN last traded around $9.03.
Dodge & Cox trimmed its position in Haleon plc ($HLN) by 3.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 146,539,663 shares of Haleon plc after selling 5,215,789 shares during the quarter. Dodge & Cox's holdings in Haleon plc were worth $1.32 billion as of its most recent filing.
Haleon plc ($HLN) Stock
Haleon plc Earnings
Haleon plc Dividend
Analysts Set New Price Targets
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.